Transperineal in vivo fluence-rate dosimetry in the canine prostate during SnET2-mediated PDT.

Advances in photodynamic therapy (PDT) treatment for prostate cancer can be achieved either by improving selectivity of the photosensitizer towards prostate gland tissue or improving the dosimetry by means of individualized treatment planning using currently available photosensitizers. The latter approach requires the ability to measure, among other parameters, the fluence rate at different positions within the prostate and the ability to derive the tissue optical properties. Here fibre optic probes are presented capable of measuring the fluence rate throughout large tissue volumes and a method to derive the tissue optical properties for different volumes of the prostate. The responsivity of the sensors is sufficient to detect a fluence rate of 0.1 mW cm(-2). The effective attenuation coefficient in the canine prostate at 660 nm is higher at the capsule (2.15+/-0.19 cm(-1)) than in proximity of the urethra (1.84+/-0.36 cm(-1)). Significant spatial and temporal intra- and inter-canine variability in the tissue optical properties was noted, highlighting the need for individualized monitoring of the fluence rate for improved dosimetry.

[1]  Timothy C Zhu,et al.  In vivo Optical Properties of Normal Canine Prostate at 732 nm Using Motexafin Lutetium–mediated Photodynamic Therapy¶ , 2003, Photochemistry and photobiology.

[2]  S Kölchens,et al.  Quasi-elastic light scattering determination of the size distribution of extruded vesicles. , 1993, Chemistry and physics of lipids.

[3]  Natalie Pomerleau,et al.  Multitasking optical fiber probes for fluence-rate and fluorescent drug monitoring in vivo , 2000, BiOS.

[4]  A Ishimaru,et al.  Optical diffusion of continuous-wave, pulsed, and density waves in scattering media and comparisons with radiative transfer. , 1998, Applied optics.

[5]  B. Wilson,et al.  Comparison of the In Vivo Photodynamic Threshold Dose for Photofrin, Mono‐ and Tetrasulfonated Aluminum Phthalocyanine Using a Rat Liver Model , 1998, Photochemistry and photobiology.

[6]  Brian C. Wilson,et al.  Photodynamic therapy of malignant brain tumors: supplementary postoperative light delivery by implanted optical fibers: field fractionation , 1991, Photonics West - Lasers and Applications in Science and Engineering.

[7]  C. Gomer,et al.  Photosensitization with derivatives of chlorin p6. , 1995, Journal of Photochemistry and Photobiology. B: Biology.

[8]  Partial Least Squares Based Decomposition of Five Spectrally Overlapping Factors , 2005, Applied spectroscopy.

[9]  I. Driver,et al.  Tumor vascular shutdown following photodynamic therapy based on polyhematoporphyrin or 5-aminolevulinic Acid. , 1994, International journal of oncology.

[10]  A. Douplik,et al.  Oxygen consumption and photobleaching in whole blood incubated with photosensitizer induced by laser irradiation , 2003 .

[11]  L. Lilge,et al.  Miniature isotropic optical fibre probes for quantitative light dosimetry in tissue. , 1993, Physics in medicine and biology.

[12]  Stephen G Bown,et al.  Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. , 2002, The Journal of urology.

[13]  Lothar Lilge,et al.  Performance evaluation of cylindrical fiber optic light diffusers for biomedical applications , 2004, Lasers in surgery and medicine.

[14]  R. Keck,et al.  Transperineal photodynamic ablation of the canine prostate. , 1996, The Journal of urology.

[15]  Lothar Lilge,et al.  Accuracy of interstitial measurements of absolute light fluence rate in the determination of tissue optical properties , 1993, Photonics West - Lasers and Applications in Science and Engineering.

[16]  S L Marcus,et al.  Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status , 1996, Photonics West.

[17]  Steven H. Selman,et al.  Computer model for photodynamic therapy of the prostate , 2000, Photonics West - Biomedical Optics.

[18]  Stuart L. Marcus,et al.  Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status. , 1996 .

[19]  M. Kattan,et al.  Radical prostatectomy for carcinoma of the prostate , 2004, Modern Pathology.

[20]  B. Wilson,et al.  Changes in in vivo optical properties and light distributions in normal canine prostate during photodynamic therapy. , 1997, Radiation research.

[21]  C J Gomer,et al.  Photodynamic therapy in the treatment of malignancies. , 1989, Seminars in hematology.

[22]  A. Chakravarti,et al.  Molecular and genetic prognostic factors of prostate cancer , 2003, World Journal of Urology.

[23]  R W Keck,et al.  The effect of transurethral light on the canine prostate after sensitization with the photosensitizer tin (II) etiopurpurin dichloride: a pilot study. , 1994, The Journal of urology.

[24]  Shi-Chung Chang,et al.  Interstitial and transurethral photodynamic therapy of the canine prostate using meso‐tetra‐(m‐hydroxyphenyl) chlorin , 1996, International journal of cancer.

[25]  C. Gomer,et al.  Clinical and preclinical photodynamic therapy , 1995, Lasers in surgery and medicine.

[26]  E. Rimm,et al.  A prospective study of physical activity and prostate cancer in male health professionals. , 1998, Cancer research.

[27]  T. Chang,et al.  Purification and characterization of liposomes encapsulating hemoglobin as potential blood substitutes. , 1992, Biomaterials, artificial cells, and immobilization biotechnology : official journal of the International Society for Artificial Cells and Immobilization Biotechnology.

[28]  Rolf Muschter,et al.  Photodynamic therapy: A new approach to prostate cancer , 2003, Current urology reports.

[29]  Brian W. Pogue,et al.  Blood Flow Dynamics after Photodynamic Therapy with Verteporfin in the RIF-1 Tumor , 2003, Radiation research.

[30]  Lothar Lilge,et al.  Spatial distribution of liposome encapsulated tin etiopurpurin dichloride (SnET2) in the canine prostate: implications for computer simulation of photodynamic therapy. , 2003, International journal of molecular medicine.

[31]  T. Foster,et al.  Photochemical oxygen consumption sensitized by a porphyrin phosphorescent probe in two model systems. , 2000, Biophysical journal.

[32]  Cesar A. Rendon,et al.  Exploiting apoptosis in photodynamic therapy: is it possible? , 2003, SPIE BiOS.

[33]  Liang-yan Xue,et al.  Photodamage to multiple Bcl-xL isoforms by photodynamic therapy with the phthalocyanine photosensitizer Pc 4 , 2003, Oncogene.

[34]  L. Clegg,et al.  Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. , 2002, Archives of internal medicine.

[35]  L. Lilge,et al.  Photodynamic therapy of intracranial tissues: a preclinical comparative study of four different photosensitizers. , 1998, Journal of clinical laser medicine & surgery.

[36]  D. Kessel,et al.  PHOTOSENSITIZATION WITH DERIVATIVES OF CHLOROPHYLL , 1989, Photochemistry and photobiology.